HDT Co., Ltd announced that it expects to receive KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.
February 27, 2024
Share
HDT Co., Ltd announced that it will issue 1,000,000 common shares at an issue price of KRW 2,000 per share for the gross proceeds of KRW 2,000,000,000 on February 28, 2024. The transaction will include participation from new investor DongKoo Bio & Pharma Co., Ltd. The transaction has been approved by the board of directors of the company. The transaction is expected to close on March 14, 2024.
The company will issue common shares through third party allocation capital increase.
Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.
DONGKOO BIO & PHARMA CO., LTD. 
